Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 6:5:49.
doi: 10.3389/fmed.2018.00049. eCollection 2018.

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma

Florence Roufosse  1
Affiliations
Review

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma

Florence Roufosse. Front Med (Lausanne). .

Abstract

Improved understanding of the contribution of eosinophils to various chronic inflammatory conditions, most notably allergic asthma, has encouraged development of monoclonal antibodies specifically targeting mediators and surface receptors involved in eosinophil expansion and activation. The pivotal role of interleukin-5 (IL-5) in eosinophil biology, its high specificity for this leukocyte subset, and its involvement in the majority of eosinophilic conditions make it a very enticing target for treatment of eosinophil-mediated disorders. Two types of antibodies have been developed to target eosinophils: antibodies against IL-5 (mepolizumab and reslizumab), and an antibody against the IL-5-receptor-alpha-chain (IL-5Rα) (benralizumab). Both types of antibodies prevent IL-5 from engaging its receptor and in addition, anti-IL-5Rα antibodies induce target-cell lysis. They have been shown to reduce circulating eosinophil counts rapidly in humans with various disorders. Herein, a brief overview of the role of IL-5 in eosinophil biology will be presented, followed by a description of the development and characteristics of antibodies targeting IL-5 or its receptor. Results of clinical trials evaluating the efficacy and safety of these new antibodies in diseases (other than eosinophilic asthma) with prominent tissue eosinophilia are reviewed, followed by safety considerations and potential future applications.

Keywords: benralizumab; eosinophilic esophagitis; eosinophilic granulomatosis with polyangiitis; hypereosinophilic syndrome; interleukin-5; mepolizumab; nasal polyposis; reslizumab.

PubMed Disclaimer

References

    1. Fulkerson PC. Transcription factors in eosinophil development and as therapeutic targets. Front Med (2017) 4:115. 10.3389/fmed.2017.00115 - DOI - PMC - PubMed
    1. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med (2002) 195(11):1387–95. 10.1084/jem.20020656 - DOI - PMC - PubMed
    1. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O’Neill KR, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science (2004) 305(5691):1773–6. 10.1126/science.1099472 - DOI - PubMed
    1. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy (2012) 42(5):712–37. 10.1111/j.1365-2222.2011.03854.x - DOI - PubMed
    1. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol (2006) 24:147–74. 10.1146/annurev.immunol.24.021605.090720 - DOI - PubMed